Tenaya Therapeutics gets FDA RMAT designation for TN-401
FDA granted Tenaya Therapeutics a Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Story updates
12:32:53 PM UTC
SquawkNews
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia BurdenAdditional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therap…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.